NME1 and melanoma: In the years to come, a number of studies reported that downregulation or loss of expression of NME1 was correlated with the onset of metastasis and poor clinical outcome in many tumor types such as melanoma, breast cancer, ovarian carcinoma, hepatocellular and laryngeal carcinoma, and several other malignancies [9].